Shanghai Securities News / China Securities Online (Reporter: Zhang Xue) — On December 26, the oral hexavalent rotavirus vaccine, independently developed by the Wuhan Institute of Biological Products under Sinopharm CNBG, completed its first dose vaccination. According to CNBG, this is the world's first vaccine covering six rotavirus serotypes to officially enter the practical application stage.
Rotavirus is a primary pathogen causing acute severe diarrhea in infants and young children, characterized by wide transmission and significant health risks. The oral hexavalent rotavirus vaccine administered in this first dose covers six major serotypes—G1, G2, G3, G4, G8, and G9—achieving full coverage of China's currently dominant circulating G-type strains for the first time. Li Ruizhen, deputy chief physician of the Child Healthcare Department at Wuhan Children's Hospital, pointed out that multivalent vaccines help expand the scope of immune protection and are of positive significance in reducing the occurrence of severe diarrhea and lowering hospitalization rates.
The product was approved for marketing in August 2025 and nationwide vaccination was launched in late December 2025.

https://finance.eastmoney.com/a/202512263602936830.html